Ellen Hoffing - Perrigo Independent Director

PRGO
 Stock
  

USD 40.57  0.40  0.98%   

  Director
Ms. Ellen Randi Hoffing is an Independent Director of the Company. Ms. Hoffing served as Chief Operating Officer and CoPresident of Neos Therapeutics, a privately held specialty pharmaceutical company that focuses on extended release liquid and orally disintegrating tablet drug development from September 2009 until April 2014. From 2006 until September 2009, she served as President and Chief Executive Officer of Applied NeuroSolutions, Inc., a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimers disease. She has also served as Chairman of Applied NeuroSolutions Board of Directors from 2007 to January 2011 and served as a director since 2006
Age: 57  Director Since 2008      
353 1 709 4000  https://www.perrigo.com
Hoffing’s extensive experience in the pharmaceutical industry includes senior positions at American Pharmaceutical Partners, in 2005, Baxter Healthcare, from 2002 to 2005, and G.D. Searle, from 1983 to 2000.

Perrigo Management Efficiency

Perrigo Company has return on total asset (ROA) of 1.05 % which means that it generated profit of $1.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (2.42) %, meaning that it created substantial loss on money invested by shareholders. Perrigo management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 3.69 B in liabilities with Debt to Equity (D/E) ratio of 0.72, which is about average as compared to similar companies. Perrigo Company has a current ratio of 2.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Perrigo until it has trouble settling it off, either with new capital or with free cash flow. So, Perrigo's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Perrigo Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Perrigo to invest in growth at high rates of return. When we think about Perrigo's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Anthony ColesRegeneron Pharmaceuticals
2017
Felix BakerSeagen Inc
2005
Robert TepperAllena Pharmaceuticals
N/A
Axel BolteAllena Pharmaceuticals
2014
Charles BakerRegeneron Pharmaceuticals
N/A
TsuJae LiuIntel Corp
2016
Gregory BaileyBiohaven Pharmaceutical Holding
2014
Susan DeckerIntel Corp
2012
Stephen SangerPfizer Inc
2009
Jack BovenderBank Of America
2014
Omar IshrakIntel Corp
2017
John McLaughlinSeagen Inc
2007
Charles GiffordBank Of America
2005
Alex GorskyInternational Business Machines
2015
George SingRegeneron Pharmaceuticals
1988
David FarrInternational Business Machines
2012
Alpna SethSeagen Inc
2018
Gregory SmithIntel Corp
2017
Charlene BarshefskyIntel Corp
2004
James McNerneyInternational Business Machines
2009
Bonnie BasslerRegeneron Pharmaceuticals
2016
Perrigo Company plc provides over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 9900 people. Perrigo Company (PRGO) is traded on New York Stock Exchange in USA and employs 9,900 people.

Perrigo Company Leadership Team

Elected by the shareholders, the Perrigo's board of directors comprises two types of representatives: Perrigo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Perrigo. The board's role is to monitor Perrigo's management team and ensure that shareholders' interests are well served. Perrigo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Perrigo's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Thomas Farrington, Executive Vice President, Chief Information Officer
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive Vice President, General Counsel, Company Secretary
Rolf Classon, Independent Chairman of the Board
Raymond Silcock, Chief Financial Officer, Executive Vice President
Shlomo Yanai, Independent Director Nominee
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Murray Kessler, President, Chief Executive Officer, Director
Erica Mann, Independent Director
Richard Sorota, Executive Vice President, General Manager - of Consumer Self-Care Americas
Gary Kunkle, Lead Independent Director
Katherine Doyle, Independent Director
Joseph Papa, Chairman and CEO
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
James Dillard, Executive Vice President, President - Consumer Self-Care Americas
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Orlando Ashford, Independent Director
Ronald Winowiecki, Acting CFO
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Herman Morris, Independent Director
Jatin Shah, Senior Vice President Chief Scientific Officer
Robert Willis, Chief Human Resource Officer, Executive Vice President
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Sharon Kochan, Executive Vice President, President - RX Pharmaceuticals
Marry Brlas, Independent Chairman of the Board
Bradley Joseph, IR Contact Officer
Ronald Janish, Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer
Uwe Rohrhoff, President CEO, Director

Perrigo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Perrigo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Perrigo Investors Sentiment

The influence of Perrigo's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Perrigo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Perrigo Implied Volatility

    
  41.24  
Perrigo's implied volatility exposes the market's sentiment of Perrigo Company stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Perrigo's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Perrigo stock will not fluctuate a lot when Perrigo's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Perrigo in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Perrigo's short interest history, or implied volatility extrapolated from Perrigo options trading.

Current Sentiment - PRGO

Perrigo Company Investor Sentiment

Most of Macroaxis users are at this time bullish on Perrigo Company. What is your perspective on investing in Perrigo Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Perrigo Company information on this page should be used as a complementary analysis to other Perrigo's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Perrigo Stock analysis

When running Perrigo Company price analysis, check to measure Perrigo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perrigo is operating at the current time. Most of Perrigo's value examination focuses on studying past and present price action to predict the probability of Perrigo's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Perrigo's price. Additionally, you may evaluate how the addition of Perrigo to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Is Perrigo's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perrigo. If investors know Perrigo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perrigo listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.64
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
0.064
Return On Assets
0.0089
Return On Equity
-0.0253
The market value of Perrigo Company is measured differently than its book value, which is the value of Perrigo that is recorded on the company's balance sheet. Investors also form their own opinion of Perrigo's value that differs from its market value or its book value, called intrinsic value, which is Perrigo's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perrigo's market value can be influenced by many factors that don't directly affect Perrigo's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perrigo's value and its price as these two are different measures arrived at by different means. Investors typically determine Perrigo value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perrigo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.